Detail akcie Mereo BioPha Sp ADS online

Business Summary: Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Mereo BioPharma Group plc - ADR revenues increased from $0K to $500K. Net loss decreased 5% to $34.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 6% to $18.8M (expense), Changes in the fair value of warrants increase from $576K (expense) to $511K (income).